Vor Bio appoints Qing Zuraw as CDO, Michel Detheux and Bo Cumbo as directors

Vor Biopharma Inc.

Resignation of director Sven (Bill) Ante Lundberg effective July 17, 2025; no disagreement cited.
Qing Zuraw appointed CDO; over 25 years in autoimmune diseases; previously led telitacicept trials at RemeGen.
Zuraw's compensation: $565k base salary, 40% target bonus, $200k signing bonus, 4.37M options, 937k RSUs.
Board expanded to 10; Michel Detheux (CEO iTeos) and Alexander Cumbo (CEO Solid Biosciences) as independent directors.
New directors receive $40k cash retainer, initial 60k options, annual 30k options per standard policy.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.